Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial. There are no randomized trials of allogeneic HCT. In the present study, updated individual patient data were collected and analyzed from studies with information on availability of matched sibling donor (used to mimic randomization) and from randomized trials of autograft versus chemotherapy. Data from 13 studies including 2962 patients, excluding Philadelphia chromosome-positive patients, showed a survival benefit for having a matched sibling donor for patients < 35 years of age (OR = 0.79; 95% CI, 0.70-0.90, P = .0003) but not for those ≥ 35 years of age (OR = 1.01; 95% CI, 0.85-1.19, P = .9; heterogeneity P = .03) because of the higher absolute risk of nonrelapse mortality for older patients. No differences were seen by risk group. There was a trend toward inferior survival for autograft versus chemotherapy (OR = 1.18; 95% CI, 0.99-1.41; P = .06). No beneficial effect of autografting was seen compared with chemotherapy in this analysis. We conclude that matched sibling donor myeloablative HCT improves survival only for younger patients, with an absolute benefit of approximately 10% at 5 years. Improved chemotherapy outcomes and reduced nonrelapse mortality associated with allogeneic HCT may change the relative effects of these treatments in the future.
Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis / Gupta, V; Richards, S; Rowe, J; Büchner, T; Hiddemann, W; Sauerland, C; Amadori, S; Rondelli, R; Testi, Am; Attal, M; Jourdan, E; Reiffers, J; Howman, A; Patel, S; Jacobs, P; Lee, S; Brunet, S; Sierra, J; Alonzo, T; Aplenc, R; Sung, L; Cutler, C; Rowe, J; Sun, Z; Tallman, M; Ljungman, P; Labar, B; Willemze, R; Suciu, S; Collette, S; Dombret, H; Thomas, X; Ifrah, N; Hunault-Berger, M; Mandelli, F; Vignetti, M; Tsimberidou, Am; Pagnano, K; da Souza, Ca; Miranda, Ec; Diaz de Heredia, C; Ortega, Jj; Cornelissen, Jj; van der Holt, B; Oh, H; Takeuchi, J; Kaizer, H; Björkholm, M; Rosenborg, A; Keating, M; Zander, A; Fielding, A; Goldstone, A; Moorman, Av; Richards, S; Bassan, R; Ravindranath, Y; Weinstein, H; Oriol, A; Ribera, Jm; Powles, R; Appelbaum, F; Baker, Luigi; Coltman, C; Crowley, J; Kopecky, K; Messner, H; Gupta, V; Akan, H; Beksac, M; Hills, R; Buck, G; Davies, K; Elphinstone, T; Evans, V; Gettins, L; Gregory, C; James, S; Mackinnon, L; Mchugh, T; Morris, P; Richards, S; Wade, R; Wheatley, K.. - In: BLOOD. - ISSN 0006-4971. - 121:2(2013), pp. 339-350. [10.1182/blood-2012-07-445098]
Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis
Amadori S;Testi AM;Mandelli F;Vignetti M;BAKER, Luigi;Crowley J;
2013
Abstract
Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial. There are no randomized trials of allogeneic HCT. In the present study, updated individual patient data were collected and analyzed from studies with information on availability of matched sibling donor (used to mimic randomization) and from randomized trials of autograft versus chemotherapy. Data from 13 studies including 2962 patients, excluding Philadelphia chromosome-positive patients, showed a survival benefit for having a matched sibling donor for patients < 35 years of age (OR = 0.79; 95% CI, 0.70-0.90, P = .0003) but not for those ≥ 35 years of age (OR = 1.01; 95% CI, 0.85-1.19, P = .9; heterogeneity P = .03) because of the higher absolute risk of nonrelapse mortality for older patients. No differences were seen by risk group. There was a trend toward inferior survival for autograft versus chemotherapy (OR = 1.18; 95% CI, 0.99-1.41; P = .06). No beneficial effect of autografting was seen compared with chemotherapy in this analysis. We conclude that matched sibling donor myeloablative HCT improves survival only for younger patients, with an absolute benefit of approximately 10% at 5 years. Improved chemotherapy outcomes and reduced nonrelapse mortality associated with allogeneic HCT may change the relative effects of these treatments in the future.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
